trending Market Intelligence /marketintelligence/en/news-insights/trending/3OCsqd0aUBVtxL7HsHXxyw2 content esgSubNav
In This List

AbbVie, J&J's Imbruvica gets FDA approval for chronic graft versus host disease

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


AbbVie, J&J's Imbruvica gets FDA approval for chronic graft versus host disease

The U.S. Food and Drug Administration approved AbbVie Inc.'s Imbruvica to treat adult patients with chronic graft-versus-host-disease who failed one or more treatments.

With this approval, Imbruvica is the first and only therapy specifically approved for adults with chronic graft-versus-host-disease, a serious and debilitating potential consequence of stem cell or bone marrow transplant.

The approval was based on the results of a phase 1b/2 trial where 67% of patients who received the treatment saw improvements in their symptoms. Also, 48% of the patients experienced sustained response for at least 20 weeks.

Imbruvica is jointly developed and commercialized by AbbVie's Pharmacyclics LLC and Janssen Biotech Inc., a Johnson & Johnson company. The companies are continuing the drug's clinical development, including phase 3 studies evaluating it in multiple disease areas.